CAPTRUST Financial Advisors
QNCX icon

CAPTRUST Financial Advisors’s Quince Therapeutics QNCX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-36
Closed -$44K – 5094
2022
Q1 		$44K Hold
36
– – ﹤0.01% 2886
2021
Q4 		$91K Buy
36
+13
+57% +$79.3K ﹤0.01% 2234
2021
Q3 		$425K Buy
23
+22
+2,200% +$350K ﹤0.01% 1112
2021
Q2 		$13K Buy
+1
New +$8.38K ﹤0.01% 3391

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

CAPTRUST Financial Advisors's QNCX Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 36 shares — an estimated $44K sold.

CAPTRUST Financial Advisors first reported a position in QNCX in Q2 2021 and held it in 4 quarters. The position peaked at $425K in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 36 Quince Therapeutics shares in Q2 2022, an estimated $44K.
  • CAPTRUST Financial Advisors first reported a position in Quince Therapeutics in Q2 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Quince Therapeutics position peaked at $425K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.